iodide I-123 ipaitomab

**Iodide I-123 ipaitomab** is a targeted radiopharmaceutical consisting of the radioisotope iodine-123 (I-123) conjugated to ipaitomab, an anti-CD45 monoclonal antibody, designed for diagnostic imaging in oncology. It functions by delivering the gamma-emitting I-123 to CD45-expressing cells, primarily in hematopoietic tissues and certain tumors, enabling single photon emission computed tomography (SPECT) visualization of tumor lesions or biodistribution for dosimetry assessment prior to therapeutic radioimmunoconjugates. Developed for applications in blood cancers like acute myeloid leukemia (AML), it leverages the norepinephrine transporter-independent uptake via antibody-mediated targeting, distinguishing it from non-targeted I-123 agents, with primary indications under investigation for leukemia imaging.